| Daniel J Muccio, MD | |
|
2315 Myrtle St Ste L90, Erie, PA 16502-4607 | |
| (814) 452-7575 | |
| (814) 452-7574 |
| Full Name | Daniel J Muccio |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 39 Years |
| Location | 2315 Myrtle St Ste L90, Erie, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1477531630 | NPI | - | NPPES |
| 001243827 | Medicaid | PA | |
| 10932893 | Other | CAQH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | MD037094E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Vincent Hospital | Erie, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Allegheny Clinic | 5395649586 | 1941 |
| Keystone Rehabilitation Systems Inc | 7012826753 | 505 |
News Archive
Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.
Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.
The Wall Street Journal: "When the Senate unveils its health-care bill, all eyes will be on the price tag. But an equally significant number may be how many people get health insurance under the legislation."
› Verified 6 days ago
| Entity Name | Allegheny Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073081493 PECOS PAC ID: 5395649586 Enrollment ID: O20040310000602 |
News Archive
Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.
Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.
The Wall Street Journal: "When the Senate unveils its health-care bill, all eyes will be on the price tag. But an equally significant number may be how many people get health insurance under the legislation."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel J Muccio, MD 2315 Myrtle St Ste L90, Erie, PA 16502-4607 Ph: (814) 452-7575 | Daniel J Muccio, MD 2315 Myrtle St Ste L90, Erie, PA 16502-4607 Ph: (814) 452-7575 |
News Archive
Graymark Healthcare, Inc. today announced financial results for the quarter ending June 30, 2010 including $1.1MM of EBITDA on $28.3MM in sales.
Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a complex composed of two brain receptors linked to schizophrenia.
RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the pharmacokinetic results of their single dose Phase 1 study with RXI-109 in healthy subjects.
Researchers at McMaster University have developed the first assessment tool of its kind for evaluating risks faced by Canadians suffering from a rare and often fatal bleeding disorder.
The Wall Street Journal: "When the Senate unveils its health-care bill, all eyes will be on the price tag. But an equally significant number may be how many people get health insurance under the legislation."
› Verified 6 days ago
Arturo Camacho, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2315 Myrtle St Ste L90, Erie, PA 16502 Phone: 814-452-7575 Fax: 814-452-7574 | |
Dr. Richard Norton Hall, MD Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 6353 Meadowrue Ln, Erie, PA 16505 Phone: 814-833-6128 | |
Dr. Brian Edward Dalton, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 120 E 2nd St, Ste 401, Erie, PA 16507 Phone: 814-459-1013 Fax: 814-459-0435 | |
Jonathan Bellotte, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 State St Fl 4, 4th Floor, Suite 401, Erie, PA 16507 Phone: 814-877-5330 | |
Mrs. Elena I Fomchenko, MD, PHD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 2315 Myrtle St Ste L90, Erie, PA 16502 Phone: 814-452-7575 | |
Dr. Isam Ahmed Khoja, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 201 State St, 8th Floor, Erie, PA 16550 Phone: 814-877-5330 Fax: 814-877-5331 |